Imunon, Inc. (IMNN) News
Track canonical SquawkNews coverage tagged to IMNN, Imunon, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 12 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
IMUNON IDMC recommends continuing Phase 2 MRD study unchanged
IMUNON said its independent monitoring committee recommended its Phase 2 MRD study of IMNN-001 continue without changes after reviewing safety data, citing no cytokine release syndrome, systemic toxicities, or serious im
EQUITY | Sep 22, 2026, 12:12 PM UTC
M
IMUNON Data Monitoring Committee backs continued Phase 2 IMNN-001
IMUNON says its Independent Data Monitoring Committee recommends continuing the Phase 2 MRD study without modification after reviewing safety data to date. It reports no cytokine release syndrome, systemic toxicities, or
EQUITY | Sep 22, 2026, 12:11 PM UTC
L
IMNN - IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review
IMNN - IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review
NEWS | Sep 22, 2026, 12:05 PM UTC
L
Imunon enters CRADA with NCI to advance IMNN-001 development
Imunon will work with the NCI Cancer Therapy Evaluation Program to evaluate IMNN-001 in new indications and combination regimens. Imunon retains ownership of its background intellectual property and can expand its IP thr
MNA | Sep 10, 2026, 01:32 PM UTC
L
IMUNON enters CRADA with National Cancer Institute for IMNN-001
IMUNON said it entered a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute to advance clinical development of IMNN-001.
EQUITY | Sep 10, 2026, 01:30 PM UTC
L
IMNN-IMUNON sets agenda and speaker lineup for 2026 R&D Day
IMNN-IMUNON announced the full agenda and speaker lineup ahead of 2026 R&D Day, highlighting IMNN-001 clinical progress.
EQUITY | Sep 09, 2026, 12:32 PM UTC
L
IMNN announces 2026 R&D Day highlighting Phase 3 OVATION 3
IMUNON says it will host a 2026 R&D Day featuring Phase 3 OVATION 3 and the clinical potential of IMNN-001.
EQUITY | Aug 26, 2026, 12:30 PM UTC
L
IMNN - IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026 - Click For Rele
IMNN - IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026
EARNINGS | Aug 04, 2026, 12:00 PM UTC
H
IMNN Reports Strong Enrollment Momentum
IMNN sees strong enrollment in phase 3 trial
EQUITY | Jul 30, 2026, 01:00 PM UTC
L
IMNN Imunon reports positive phase 2 mrd clinical data for imnn-001, demonstrating the successful overcoming of historical il-12 safety barr
IMNN Imunon reports positive phase 2 mrd clinical data for imnn-001, demonstrating the successful overcoming of historical il-12 safety barriers in frontline ovarian cancer Imunon - imnn-001 demonstrates lower mrd rate,
EQUITY | Jul 21, 2026, 01:01 PM UTC
L
Imunon Says Jeffrey Church To Retire As Interim CFO Effective July 1, 2026; Appoints Josh Blacher As Interim CFO Effective July 1, 2026
On June 29, 2026, Jeffrey Church informed Imunon, Inc. (the "Company") of his intent to retire from the position of interim Chief Financial Officer (a position he has held since January of 2026), effective July 1, 2026 (
EQUITY | Jun 30, 2026, 08:44 PM UTC
M
IMNN Continues Phase 3 Study
IMUNON's Data Monitoring Committee recommends continuation of Phase 3 OVATION 3 Study without modification
EARNINGS | Jun 23, 2026, 12:02 PM UTC